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Abstract
Hypertension continues to be an important public health concern because of its associated morbidity, mortality
and economic impact on the society. It is a significant risk factor for cardiovascular, cerebrovascular and renal
complications. It has been estimated that by 2025, 1.56 billion individuals will have hypertension. The increasing
prevalence of hypertension and the continually increasing expense of its treatment influence the prescribing
patterns among physicians and compliance to the treatment by the patients. A number of national and
international guidelines for the management of hypertension have been published. Since many years ago, diuretics
were considered as the first-line drugs for treatment of hypertension therapy; however, the recent guidelines by the
Joint National Commission (JNC8 guidelines) recommend both calcium channel blockers as well as angiotensin-
converting enzyme inhibitors as first-line drugs, in addition to diuretics. Antihypertensive drug combinations are
generally used for effective long-term management and to treat comorbid conditions. This review focuses on the
antihypertensive medication utilization, their cost factors, adherence to treatment by patients, and physicians’
adherence to guidelines in prescribing medications in different settings including Indian scenario. The
antihypertensive medication prescribing pattern studies help in monitoring, evaluation and necessary modifications
to the prescribing habits to achieve rational and cost-effective treatment. Additionally, periodic updating of
recommended guidelines and innovative drug formulations, and prescription monitoring studies help in rational
use of antihypertensive drugs, which can be tailored to suit the patients' requirements, including those in the
developing countries.
Background
Hypertension is the most common modifiable risk factor
for cardiovascular diseases (CVD), stroke and renal fail-
ure [1]. It is the second leading cause of chronic kidney
disease (CKD). It is estimated that more than one billion
adults are hypertensive worldwide and this figure is pro-
jected to increase to 1.56 billion by the year 2025, which
is an increase of 60 % from 2000. Cardiovascular dis-
eases and Hypertension are accounting for loss of 4 %
gross domestic product for low and middle income
countries annually which is amounting 500 billion USD
[2]. Clinical evidence suggests that lowering blood pres-
sure (BP) with antihypertensive drugs reduces the risk of
myocardial infarction, stroke, heart failure, revasculariza-
tion procedures and end-stage renal diseases in hyper-
tensive patients [3].
The increasing prevalence of hypertension has been at-
tributed to population growth, ageing and behavioral
risk factors, such as unhealthy diet, excess use of alcohol,
sedentary lifestyle, obesity, and exposure to persistent
stress. A whopping 9.4 million deaths occur worldwide
every year because of hypertension [4], with it being re-
sponsible for about 50 % of mortality due to heart disease
and stroke [5]. Epidemiological studies demonstrated that
prevalence of hypertension is increasing rapidly in
India, varying from 4 to 15 % in urban and 2-8 % in
rural population [6, 7].
Several guidelines have been developed worldwide for
the management of hypertension, and these serve as ref-
erence standards for clinical practitioners. However,
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many clinicians practice their own prescribing pattern in
treating hypertensive patients according to their clinical
experience. Primary care physicians need to be empow-
ered in appropriate and evidence-based management of
hypertension. A review of these prescribing patterns
and guideline-based use of antihypertensive medica-
tions can give better insights into the concept of
personalised, yet cost-effective pharmacological man-
agement of hypertension.
Hypertension pharmacotherapy and guidelines
Antihypertensive drugs are prescribed mainly to reduce
the morbidity and mortality caused by hypertension and
its complications. Many a time, patients require more
than one drug for effective control of hypertension. Vari-
ous classes of antihypertensive drugs like diuretics, inhibi-
tors of the renin-angiotensin system, calcium channel
blockers (CCB) and beta blockers (BB) have been shown
to reduce complications of hypertension and may be used
for initial drugtherapy [8].
Since the need to improve the control of hypertension
is well acknowledged, several guidelines on its classifica-
tion and management have been developed. Some of the
bodies which have developed guidelines are American
Society of Hypertension/ International Society of hyper-
tension (ASH/ISH), Joint National Committee (JNC) on
Detection, Evaluation, and Treatment of High Blood
Pressure, European Society of Hypertension (ESH)/Euro-
pean Society of Cardiology (ESC), National Institute for
Health and Care Excellence (NICE) and Japanese Society
of Hypertension. The JNC 8 guidelines published in
2014 are the most recent guidelines for the management
of hypertension in different clinical settings. These
guidelines were developed based on a systematic review
of literature to help clinicians, especially the primary
care physicians [3]. Despite these guidelines, and also
evidence showing that hypertension is a major public
health concern, many clinicians fail to assess BP rou-
tinely, and in those with a diagnosis of hypertension, do
not start treatment or titrate the dosage of the drugs ef-
fectively [9]. The available guidelines recommend differ-
ent goal BP levels and drug treatment options according
to patients’ individual clinical need (see Table 1).
Studies have shown that the application of guidelines
to clinical practice improve the treatment outcomes. Ac-
cording to a retrospective study by Jackson et al. on
19,258 patients, applying JNC-7 guidelines to practice
helped in achieving better BP control. Blood pressure
control in the before-JNC 7 cohort was 40.8 % vs.
49.3 % in the after-JNC 7 cohort (p < 0.0001) [10].
In another older study conducted to assess whether
the publication of JNC 6 (1997) and WHO/ISH (1999)
guidelines, and the development of new drugs improved
BP control, follow-up of 150 patients from 1991 to 2001
showed that BP control increased from 31 % initially, to
43 % in 1996 and finally to 57 % in 2001. Both younger
and older patients showed similar improvement during
these 10 years. The authors concluded that improved BP
control was because of increased use of ACEIs and
CCBs, lifestyle modifications and improved awareness
about the disease condition and the need for effective
management [11]. Jeschke et al. demonstrated that anti-
hypertensive therapy prescribed by physicians specialized
in complementary and alternative medicine (CAM) in
Germany complied with the German Hypertension Soci-
ety guidelines. Most patients were treated with conven-
tional antihypertensives like BBs and ACEIs. A thiazide
diuretic with ACEI was the most frequent combination
prescribed [12].
Evaluating prescribing pattern of antihypertensive drugs
There have been several studies evaluating the prescrib-
ing pattern of antihypertensive drugs worldwide. Over
the past 20 years, there has been a consistent increase in
the use of ACEIs, ARBs and CCBs and many robustly
conducted clinical studies have showed no consistent
differences in antihypertensive efficacy, side effects and
quality of life within these drug classes [13]. This has
been supported by a retrospective time series data from
2007 to 2012 noted that the consumption of antihyper-
tensive drugs in China nearly doubled [14]. The most
frequently prescribed antihypertensive drug classes were
CCBs and ARBs, with prescriptions of the latter increas-
ing most rapidly [14].
Liu and Wang demonstrated that in 6,536 newly-
diagnosed cases of uncomplicated hypertension, CCBs
and BBs were the most prescribed antihypertensive med-
ications. Surprisingly, the prescription rate of thiazide di-
uretics which are the least expensive, and well-known
first-line antihypertensive therapy was low (8.3 % mono-
therapy and 19.9 % overall) [15].
Joseph et al. used Phadke’s criterion for assessment of
appropriateness of prescribing. They observed that most
patients were being treated with two or more drugs and
CCBs were most frequently prescribed antihypertensive
medicines. Similar to other studies, 67.92 % of the pa-
tients were prescribed more than one drug, with the
most commonly used combination being CCB + BB +
alpha-blocker (7.55 %). Based on Phadke’s evaluation cri-
teria, 87.27 % of prescriptions were found rational [16]..
In another drug utilization study, 645 prescriptions were
analyzed. A total of 697 antihypertensive drugs pre-
scribed, of which 33.57 % were ARBs, 16.79 % ACEIs,
13.63 % were BBs and 11.91 % CCBs. About 32 % of the
antihypertensives prescribed were from the essential
medicine list [17].
In a National Health and Nutrition Examination Sur-
vey conducted on subjects aged ≥18 years, it was
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observed that combination therapy regimens helped to
achieve BP goals, with single-pill fixed dose combination
(FDC) and multiple-pill combinations being associated
with a 55 % and 26 % increased likelihood of BP control,
respectively when compared to monotherapy. A signifi-
cant increase in the use of multiple antihypertensive
agents from 36.8 % to 47.7 % (p < 0.01), with an in-
creased use of thiazide diuretics, BBs, ACEIs, and ARBs
by 23 %, 57 %, 31 %, and 100 %, respectively was ob-
served [18].
Al-Drabah et al. observed that majority of subjects in
their study were prescribed monotherapy, followed by
two drugs. A few others required three of more drugs.
While ACEIs were the most commonly prescribed
monotherapy, diuretics were the most commonly pre-
scribed drugs in combination therapy. The researchers
further observed that target BP control was not achieved
in most patients which imply that monotherapy may not
be sufficient for achieving adequate BP control in major-
ity of the patients [19]. The notable findings of various
studies have been presented in Table 2. As per our
knowledge, there is no recent data on international vari-
ation in prescribing antihypertensive drugs, which can
help clinicians to keep them updated with the recent
trends.
Antihypertensive drug utilization and adherence
Antihypertensive medication utilization, adherence to
treatment by patients, and physicians’ adherence to
guidelines in prescribing medications have been studied
in different settings. Many of them have noted full, par-
tial or no-adherence in some studies. Studies suggest
that formulators of guidelines should evolve treatment
protocols which needs less frequent monitoring by phys-
ician, so as to suit developing countries patients. Glo-
bally, all guidelines address that guidelines are just to
guide but physicians need to follow a patient-centric ap-
proach. Treatment strategies for developing countries,
where access to health care system is less compared to
developed countries, need to be simple, economic and
Table 1 Guideline comparisons of goal BP and initial drug therapy for adults with hypertension
Guideline Population Goal BP,
mmHg
Initial drug treatment options
JNC 8: 2014 Hypertension Guideline [3] General ≥60 y <150/90 Nonblack: thiazide-type diuretic, ACEI, ARB,
or CCB; black: thiazide-type diuretic or CCB
General <60 y <140/90
Diabetes <140/90
CKD <140/90 ACEI or ARB
ESH/ESC 2013 [42] General nonelderly <140/90 Diuretic, BB, CCB, ACEI, or ARB
General elderly <80 y <150/90
General ≥80 y <150/90
Diabetes <140/85 ACEI or ARB
CKD no proteinuria <140/90
CKD + proteinuria <130/90
Canadian Hypertension Education
Program (CHEP) 2014 [43]
General <80 y <140/90 Thiazide, BB (age <60y), ACEI (nonblack), or ARB
General ≥80 y <150/90
Diabetes <130/80 ACEI or ARB with additional CVD risk ACEI, ARB, thiazide,
or dihydropyridine CCB without additional CVD risk
CKD <140/90 ACEI or ARB
American Diabetes Association
(ADA) 2013 [44]
Diabetes <140/80 ACEI or ARB
Kidney Disease: Improving Global
Outcome (KDIGO) 2012 [45]
CKD, no proteinuria ≤140/90 ACEI or ARB
CKD + proteinuria ≤130/80
NICE 2011 [46] General <80 y <140/90 <55 y: ACEI or ARB
General ≥80 y <150/90 ≥55 y or black: CCB
International Society for Hypertension in
Blacks (ISHIB) 2010 [47]




Korean Society of Hypertension Guidelines for
the Management of Hypertension 2013 [48]
Elderly (>65 years) <140/90 ACEIs, CCBs and diuretics; BBs should be limited
to special scenarios
Diabetes <140/85
Stroke, CAD and CKD 140/90 Combination therapy of ARBs, CCBs and diuretics
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forced time bound titration by the primary care phys-
ician and not by the specialist or the tertiary care phys-
ician, in order to reach maximum number of patients.
A study conducted in India pointed to a common
trend that the study patients were on multiple therapies
with at least two antihypertensives. This pattern is rec-
ommended by guidelines, which state that small doses of
different classes of antihypertensive drug are more bene-
ficial than a high dose of one [20]. In a recent study, it
has been noted that in India, the antihypertensive
utilization pattern is in accordance with the international
guidelines for treatment of hypertension. There is con-
siderable use of different antihypertensive drug combina-
tions and such practice has a positive impact on the
overall BP control [21].
In a meta-analysis, Murphy et al. noted that no con-
sistent differences were observed in the rates of
utilization or adherence to drugs for CVDs or diabetes
in subjects living in urban and rural settings [22]. Odili
et al. studied the role of physicians in the overall man-
agement of hypertension and their adherence to JNC 7,
WHO/ISH and ESH guidelines. They concluded that
physicians in this study fairly complied with hyperten-
sion management guidelines. However, they did not ap-
pear to recommend lifestyle modification to their
patients [23]. On the contrary, a study conducted in
Malaysia, observed that doctors poorly adhered to Ma-
laysian Clinical Practice Guideline (CPG) in hypertensive
patients with diabetes and left ventricular hypertrophy.
A better hypertension control was seen with ACEIs and
guidelines-adherent therapy [24].
In another study by Abdulameer et al., 85.30 % of the
prescriptions were in accordance to guidelines [25]. It
was observed that the treatment approach for cardiac
complicated hypertension followed JNC 7 guidelines, ex-
cept the lack of add-on therapy practice (ARBs, aldoster-
one antagonist). The prescribing practice was found in
compliance with the Eritrean National treatment
guideline 2003 [26]. In a multicenter study, it was noted
that even though physicians self-reported that they were
aware of and implement hypertension guidelines in daily
practice, a significantly lower agreement rate between
physicians’ practice and European guidelines was de-
tected. It was also found that more than one-fourth of
high risk hypertensive patients remained untreated, half
of them remained uncontrolled, and almost 40 % of low-
risk patients received medications unreasonably [27].
Interestingly, in another study, multifaceted compre-
hensive implementation of a hypertension guideline did
not exert an impact on general practitioners’ prescribing
of antihypertensive drugs for drug-treated patients with
hypertension, even though the participating general
practitioners rated themselves as highly motivated to
treat according to the guidelines [28].
Table 3 summarizes the observations of above quoted
studies. It can be noted that physicians seemed to be
well-aware of clinical trials on compliance with hyper-
tension treatment, which showed the compliance rates
were good with monotherapy, average with two separate
drugs (pills), poor when more than two pills were used
and hence switched over from monotherapy to single
pill FDC. This strategy will offset the side-effects of max-
imum dose of one class of drug, simultaneously attract-
ing the synergistic effects of different classes of drugs at
low doses. The other advantages of single pill FDC being
low cost compared to multiple pills of different classes
of drugs apart from better compliance.
Cost implications in antihypertensive drugs Use
The cost of medications has always been a barrier to an
effective treatment. The increasing prevalence of hyper-
tension and the continually increasing expense of its
treatment influence the prescribing patterns among phy-
sicians and compliance to the treatment by the patients.
In developing countries like India, unlike developed
countries, patients are not covered by insurance schemes
Table 2 Findings from different studies conducted to evaluate prescribing pattern of antihypertensive drugs
Author name No. subjects involved Mono-/combination
therapy prescribed
Antihypertensive drug class Observation/Remarks
Caceres et al. [13] 100 % of the Extremadura
population
Monotherapy ARBs, ACEIs Use of ARBs increased over ACEIs
Xu et al. [14] 59 hospitals’ databases Monotherapy CCBs, ARBs, ACEIs, BBs,
and diuretics
The top-prescribed antihypertensive
drug classes were CCBs and ARBs
Liu and Wang [15] 6,536 Mono and combination CCBs (17.7 %), CCBs +
beta-blockers (7.7 %)
CCBs and BBs were the most prescribed
antihypertensives
Joseph et al. [16] 165 Two or more CCB 87.27 % prescriptions were found rational
Beg et al. [17] 645 Two or more ARB 225 antihypertensives were from essential
medicines list
Gu et al. [18] 9320 Multiple ARB With Single pill combination 55 % likelihood
of BP control
Al-Drabah et al. [19] 416 Mono (192) ACEIs Most patients did not achieve target BP
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and are paying out of their pockets for their healthcare.
Therefore, they would benefit if physicians provide bet-
ter services based on rational and cost-effective drug
prescription [29].
According to a cost analysis study by Rachana et al.,
alpha-blockers were the highest ranked in terms of cost
utilized per year followed by ACEIs, ARBs, CCBs, BBs
and diuretics in the same order. Thus they found di-
uretics to be the most cost-effective antihypertensive to
be prescribed [30]. Similarly, Amira et al. observed that
diuretics were the most cost-effective drugs for hyper-
tension [31]. Additionally, the cost of drugs varied based
on the type of hospitals, whether government or private,
according to a study by Rimoy et al., the costs of nifedi-
pine, bendrofluazide and frusemide were about five to
six times higher in private hospitals than at the
government-owned pharmacies [8].
Noteworthy is that adherence to guidelines while pre-
scribing antihypertensive drugs results in substantial sav-
ings in prescription costs [32].
The presence of comorbidities further adds to the
problem of increased economic burden. Osibogun and
Okwor demonstrated a statistically significant association
between co-morbid conditions and higher prescription
costs with 73.7 % and 63.2 % of those with diabetes and
renal disease respectively having prescription costs in the
high cost group (p < 0.05) [33]. The cost implication find-
ings from the above studies are summarized in Table 4.
Use of antihypertensives in special population
The management of hypertension needs special atten-
tion in patient population such as, elderly, pediatrics,
pregnant women, and hypertension associated with co-
morbidities. Often it qualifies for combination therapy
to achieve target BP levels. There are several studies,
which evaluated the prescription pattern of antihyper-
tensive drugs in such patient population. In a prospect-
ive, observational study conducted on geriatric
antihypertensive patients, it was noted that the most
common drug classes prescribed were CCBs (37 %) and
ACEIs (21 %), and amlodipine was the most commonly
prescribed drug (37 %). The most common anti-
hypertensive FDC prescribed was telmisartan + hydro-
chlorothiazide (15 %) and most common two drug com-
bination therapy was amlodipine + atenolol (7 %) [34]. In
another study by Fadare et al., antihypertensive drugs
accounted for 30.6 % of the total prescriptions of 220
elderly patients. The authors opined that physicians
should be specifically trained regarding prescribing to
the geriatric population [35].
An observational and cross-sectional prospective pre-
scription audit study was carried-out to evaluate antihy-
pertensive drug prescription patterns, rationality and
adherence to JNC 7 guidelines in postmenopausal
women. It was noted that ARBs were frequently pre-
scribed as monotherapy and 31.6 % of patients were on
a two-drug combination. Majority of the prescriptions
Table 3 Observations from different studies highlighting antihypertensive drug utilization and adherence
Author Name Number of subjects
involved
Observation/Remarks
Xavier et al. [20] 380 patients Small doses of different classes of antihypertensive drug are more beneficial than a high dose
of one
Shipra et al. [21] 22 prescription pattern
monitoring studies
Antihypertensive utilization pattern is in accordance with the international guidelines different
antihypertensive drug combinations in practice has a positive impact on the overall BP control
Murphy et al. [22] 51 studies No significant differences in urban versus rural settings
Odili et al. [23] 501 case notes Fair compliance with stated guidelines
Ahmad et al. [24] 13 doctors for 320
hypertensive patients
Doctors poorly adhered to Malaysian Clinical Practice Guideline (CPG)-2008 in hypertensive
patients with diabetes and LVH. A better hypertension control was seen with ACEIs and
guidelines-adherent therapy
Abdulameer et al. [25] 303 Cardiac complicated
hypertension
85.30 % adherence to guidelines
Table 4 Cost implication findings from various studies





Rachana et al. [30] 300 prescriptions Mono (48.94 %), CCB Costliest - Alpha-blocker
Cost effective - Diuretic
Amira and Okubadejo [31] 225 black patients CCB Cost effective - Amiloride
Rimoy [8] 600 patients Diuretics Govt. shops drugs 5–6 times cheaper than private shops
Fisher and Avorn [32] 133,624 patients Combination (CCB + ACEI) Adherence to guidelines result in savings
Osibogun and Okwor [33] 147 prescriptions Diuretics 79.6 % Co-morbid conditions had high cost prescriptions
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showed non-adherence as per recommendations for pre-
hypertension. The study concluded that except polyphar-
macy, antihypertensive prescription trends largely adhere
to existing guidelines and are rational [36].
Though there is a scarcity of sufficient data in Indian
context, some authors have evaluated antihypertensive
medication use in hypertensive diabetes mellitus pa-
tients. In a cross-sectional study, Dhanaraj et al. ob-
served that ACEIs were most commonly prescribed
antihypertensives (59 %) and most of the patients (55 %)
were on multiple drug therapy. In this study, although
prescribing pattern of antihypertensives was in accord-
ance with guidelines, there still remained a significant
number of patients with uncontrolled hypertension [37].
In a similar patient population, Janagan et al. observed
that most of the patients received more than one an-
tihypertensive (75.2 %), with a combination of ACEIs
and thiazide diuretics being the most common. This
pattern was compliant with JNC7 guidelines [38]
Hussain et al. conducted a retrospective, randomized,
non-interventional study in 117 subjects to evaluate
patterns of drug therapy among diabetic hypertensive
patients with other complications. It was found that
the most common drug administered for diabetes was
metformin, whereas for hypertension, it was telmisar-
tan. There was a positive relationship between fasting
blood glucose and systolic blood pressure. The not-
able gap in the present prescribing pattern was found
to be underutilization of diuretics [39].
Adolescent hypertensives seem to be undertreated,
with only 23 % of them receiving antihypertensive
prescription, according to a study by Yoon et al. Fur-
ther, ACEIs were the most frequently prescribed
monotherapy [40].
In a study by St. Peter et al. on hypertensive subjects
on dialysis, the prescription patterns varied by dialysis
modality in the initial six months. Further, it was ob-
served that majority of patients who were on BBs, drugs
inhibiting the renin angiotensin system, and dihydropyri-
dine CCBs at 6 months of dialysis did not take prescrip-
tions for these drugs by month 24. Additionally, the
specific drugs prescribed varied based on factors like
race/ethnicity, age and presence of comorbidities [41]
The key observations of the studies discussed are sum-
marized in Table 5.
Conclusion
The continued challenges in the management of hyper-
tension still need special attention. A number of national
and international guidelines for the management of hyper-
tension have been published highlighting mono- or com-
bination therapy according to the BP levels and associated
comorbidity. Worldwide, hypertension treatment strat-
egies have varied widely over time in terms of initial drug
of choice from diuretic to ACEI/ ARB/ CCB, from mono-
therapy to low dose combination single pill therapy.
National health policy makers should consider evaluation
and treatment of hypertension as a right in public health
system for better outcomes in terms of morbidity and
mortality from hypertension. The evaluation pattern,
patient adherence to the treatment, physician adherence
to hypertension management guidelines, cost implications
and other data concerning comorbid conditions have been
explored in many clinical studies. Inspite of these data and
published guidelines, inconsistencies exist towards treat-
ment approach, because of which physicians sometimes
have to individualize the therapy, based on specific patient
characteristics and response to treatment. In developing
countries like India, more systematic studies are required
on the evaluation of prescribing patterns and guideline-
based antihypertensive medications’ use, which can be
tailored to suit the patients' requirements.
Table 5 Observations of antihypertensives use in special population from various studies
Author Name Number of Subjects Involved Observation/Remarks
Altaf et al. [34] 100 geriatric patients The drug class most commonly prescribed was CCBs and the anti-hypertensive drug
combinations were considerable, and this practice impacted positively on the overall BP control.
Fadare et al. [35] 220 elderly patients Antihypertensives accounted for 30.6 % prescriptions
Tondon et al. [36] 500 prescriptions to PMW Adherence rates to JNC-7 were adequate in Stage 1, hypertensive emergency and urgency.
It was inadequate in pre-hypertension and Stage 2 hypertension.
Dhanaraj et al. [37] 1186 hypertensive patients
with type 2 DM patients
Adhered to guidelines
Janagan et al. [38] 85 hypertensive patients
with type 2 DM
Prescription pattern was in accordance with the JNC 7 recommended treatment of
hypertension with type 2 DM
Hussain et al. [39] 117 hypertensive patients
with type 2 DM
Most common drug used was telmisartan. A positive relationship between fasting blood
glucose and SBP observed. Underutilization of diuretics was noted.
Yoon et al. [40] 4296 adolescent hypertensives Only 23 % received antihypertensive prescription
St. Peter et al. [41] 13072 adult patients on
dialysis
Considerable proportions of patients with prescriptions for BBs, renin angiotensin system
agents, and dihydropyridine CCBs in month 6 no longer had prescriptions for these
medications by month 24.
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